Team:UC Chile/Accomplishments

From 2012.igem.org

(Difference between revisions)
(Judging Criteria)
 
(9 intermediate revisions not shown)
Line 1: Line 1:
{{UC_Chile4}}
{{UC_Chile4}}
-
 
-
== Accomplishments ==
 
== Judging Criteria ==
== Judging Criteria ==
-
We believe our team deserves the following medal:  ☐Bronze ☐Silver ☐Gold
+
We believe our team deserves the following medal:  ☐Bronze ☐Silver ✓Gold
Because we met the following criteria  
Because we met the following criteria  
Line 12: Line 10:
[[File:UC_Chile-bronze.jpg|left|50 px]]
[[File:UC_Chile-bronze.jpg|left|50 px]]
✓ Team registration
✓ Team registration
-
<br>Complete Judging form
+
<br>Complete Judging form
<br>✓ Team Wiki
<br>✓ Team Wiki
-
<br>☐ Present a poster and a talk at the iGEM Jamboree
+
<br>☐ Present a poster and a talk at the iGEM Jamboree (Well, we are going to so next week!)
<br>✓ At least one new submitted and well-characterized standard BioBrick Part or Device. A new application of and outstanding documentation (quantitative data showing the Part’s/ Device’s function) of a previously existing BioBrick part in the “Experience” section of that BioBrick’s Registry entry also counts.
<br>✓ At least one new submitted and well-characterized standard BioBrick Part or Device. A new application of and outstanding documentation (quantitative data showing the Part’s/ Device’s function) of a previously existing BioBrick part in the “Experience” section of that BioBrick’s Registry entry also counts.
-
''We submitted parts [http://partsregistry.org/Part:BBa_K743000 BBa_K743000] and [http://partsregistry.org/Part:BBa_K743001 BBa_K743001] wich were verified by digestion and sequencing. The functioning of these parts was extensively proved by our succesfull transformation of synechocystis, what is well documented in our [https://2012.igem.org/Team:UC_Chile/Cyanolux/Results results].
+
<i>We submitted parts [http://partsregistry.org/Part:BBa_K743000 BBa_K743000] and [http://partsregistry.org/Part:BBa_K743001 BBa_K743001] which were verified by digestion and sequencing. The functioning of these parts was extensively proved by our successful transformation of synechocystis that is well documented in our [https://2012.igem.org/Team:UC_Chile/Cyanolux/Results results].
We also characterized the functioning of KanR resistance genes [http://partsregistry.org/Part:BBa_P1003 P1003] and [http://partsregistry.org/Part:BBa_P1007 P1007] in Synechocystis PCC6803.
We also characterized the functioning of KanR resistance genes [http://partsregistry.org/Part:BBa_P1003 P1003] and [http://partsregistry.org/Part:BBa_P1007 P1007] in Synechocystis PCC6803.
-
Lastly, we quantitatively characterized the [http://partsregistry.org/Part:BBa_K325909 Luxbrick] in different temperature, o.d, glucose concentration and growth fase conditions.''
+
Lastly, we quantitatively characterized the [http://partsregistry.org/Part:BBa_K325909 Luxbrick] in different temperature, O.D, glucose concentration and growth fase conditions.</i>
 +
<i>Regarding to failed parts characterization, we made a [http://partsregistry.org/Part:BBa_K743014:Experience luciferase bioluminescence assay] for [http://partsregistry.org/Part:BBa_K743014 BBa_K743014] and for [http://partsregistry.org/Part:BBa_K743015 BBa_K743015], what proved wrong the [http://partsregistry.org/Part:BBa_K743003 Pta promoter].</i>
 +
<i> A [http://partsregistry.org/Part:BBa_K325905:Experience luciferase bioluminescence assay] was also made to test the Bacterial Lux reporter CDEG pλ AB [http://partsregistry.org/Part:BBa_K325905 BBa_K325905].
<big> Silver: </big> In addition to the Bronze Medal requirements...<br>
<big> Silver: </big> In addition to the Bronze Medal requirements...<br>
[[File:UC_Chile-silver.jpg|left|50 px]]<br>✓ Demonstrate that at least one new BioBrick Part or Device of your own design and construction works as expected
[[File:UC_Chile-silver.jpg|left|50 px]]<br>✓ Demonstrate that at least one new BioBrick Part or Device of your own design and construction works as expected
-
''Parts [http://partsregistry.org/Part:BBa_K743000 BBa_K743000] and [http://partsregistry.org/Part:BBa_K743001 BBa_K743001] worked as expected in Synechocystis double homologous recombination transformations.''
+
Parts [http://partsregistry.org/Part:BBa_K743000 BBa_K743000] and [http://partsregistry.org/Part:BBa_K743001 BBa_K743001] worked as expected in Synechocystis double homologous recombination transformations.
-
''Part [http://partsregistry.org/Part:BBa_K743017 BBa_K743017] showed inducible expression as planned.
+
Part [http://partsregistry.org/Part:BBa_K743017 BBa_K743017] showed inducible expression as planned.
-
Device [http://partsregistry.org/Part:BBa_K743006 BBa_K743006] showed the right results, i.e was usefull for transformation and selection in Synechocystis.''
+
Device [http://partsregistry.org/Part:BBa_K743006 BBa_K743006] showed the right results, i.e was useful for transformation and selection in Synechocystis.</i>
-
<br>✓Characterize the operation of at least one new BioBrick Part or Device and enter this information in the “Main Page” section of that Part’s/Device’s Registry entry
+
<br>✓Characterize the operation of at least one new BioBrick Part or Device and enter this information in the “Main Page” section of that Part’s/Device’s Registry entry.
 +
 
 +
<i>Device [http://partsregistry.org/Part:BBa_K743006 BBa_K743006] undergoes double homologous recombination in Synechocystis PCC6803 and confers kanamycin resistance. Other sequences can be added to it and its effectiveness remains as shown in [http://partsregistry.org/Part:BBa_K743005 BBa_K743005]</i>
-
''Device [http://partsregistry.org/Part:BBa_K743006 BBa_K743006] undergoes double homologous recombination in Synechocystis PCC6803 and conferes kanamycin resistance. Other sequences can be added to it and its effectiveness remains as shown in [http://partsregistry.org/Part:BBa_K743005 BBa_K743005]
 
-
''
 
Line 38: Line 38:
☐ Help another iGEM team by, for example, characterizing a part, debugging a construct, or modeling or simulating their system.
☐ Help another iGEM team by, for example, characterizing a part, debugging a construct, or modeling or simulating their system.
<br>✓Outline and detail a new approach to an issue of Human Practice in synthetic biology as it relates to your project, such as safety, security, ethics, or ownership, sharing, and innovation.
<br>✓Outline and detail a new approach to an issue of Human Practice in synthetic biology as it relates to your project, such as safety, security, ethics, or ownership, sharing, and innovation.
-
We proposed a new and simple biosafety strategy designed to be easily adopted in all biobricks. It will need minimal imputs. For more information please check our [https://2012.igem.org/Team:UC_Chile/Biosafety biosafety] section.
+
 
-
On the other hand, we organized a Synthetic Biology workshop
+
<i>We proposed a new and simple biosafety strategy designed to be easily adopted in all biobricks. It will need minimal imputs. For more information please check our [https://2012.igem.org/Team:UC_Chile/Biosafety biosafety] section.
 +
Furthermore, we organized a Synthetic Biology workshop with worldwide renown investigators in the field as lecturers. This will be the first occasion of its kind in Chile and we are sure its going to be a milestone in the history of SynBio in our country. If you want to know more about this set of conferences visit [https://2012.igem.org/Team:UC_Chile/Workshop this link]</i>
 +
 
 +
<html>
 +
<a href="https://2012.igem.org/Team:UC_Chile/Attribution"><img src="https://static.igem.org/mediawiki/2012/a/ab/UC_Chile-Continue_button.jpg" align="right">
 +
</html>
 +
 
{{UC_Chilefooter}}
{{UC_Chilefooter}}

Latest revision as of 03:48, 27 September 2012

Project: Luxilla - Pontificia Universidad Católica de Chile, iGEM 2012